NĒRx BioSciences
Indianapolis, US · 2 known investors
Find your way into NĒRx BioSciences
NĒRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.
Founders & leadership
Investors · 2
Reported raises · per SEC filings
Form D private placements▶$200KraisedNov 2021 · 3 investors · BiotechnologyRule 506(b)
▶$200KraisedNov 2021 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John J. TurchiExecutive Officer, Director
- Katherine PawelczakExecutive Officer, Director
- Trent CarrierDirector
- Offering amount
- $400K
- Amount sold
- $200K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$850KraisedJan 2019 · 9 investors · BiotechnologyRule 506(b)
▶$850KraisedJan 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas BallExecutive Officer, Director
- John J. TurchiExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $850K
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $293K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $299.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $299.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2012 | $229.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does NĒRx BioSciences do?
- NĒRx Biosciences develops small molecule inhibitors targeting DNA damage sensor proteins for cancer treatment, with initial focus on difficult-to-treat lung and ovarian cancers. The company builds on two decades of academic research from Indiana University's School of Medicine on DNA damage and repair mechanisms.
- Who founded NĒRx BioSciences?
- NĒRx BioSciences was founded by John Turchi.
- Who are NĒRx BioSciences's investors?
- NĒRx BioSciences's investors include Elevate Ventures, IU Ventures.
- Where is NĒRx BioSciences headquartered?
- NĒRx BioSciences is headquartered in Indianapolis, US.